Charles River Laboratories

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Protagen, Charles River form marketing alliance

Friday, October 28, 2011 10:39 AM

Protagen and Charles River Laboratories International have formed a strategic marketing & sales alliance.

More... »

ShangPharma acquires Charles River’s Shanghai facility

Monday, October 24, 2011 10:49 AM

ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has acquired the assets in Charles River Laboratories International’s Shanghai research facility.

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

ADDF, Charles River collaborate in research award program

Wednesday, July 13, 2011 10:27 AM

The Alzheimer's Drug Discovery Foundation (ADDF) is collaborating with Charles River Laboratories International, a provider of early-stage drug development products and services, to create a new research award program entitled Use of Aged Rats as a Relevant Pre-clinical Model for the Development of Therapies for Cognitive Aging and Alzheimer's Disease.  The program is made possible through a donation from Charles River's Discovery Services business and funds from the ADDF.

More... »

Charles River, Pfizer collaborate

Friday, March 4, 2011 02:19 PM

Charles River Laboratories has signed a marketing and distribution agreement with Pfizer to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under this agreement, CRL will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.

More... »

WuXi reports 2Q revenue growth after Charles River deal fails

Friday, August 6, 2010 08:45 AM

Shanghai-based WuXi PharmaTech will receive a breakup fee of $30 million from Charles River Laboratories International, whose previously announced purchase of Wuxi was terminated by mutual agreement due to Charles River shareholder opposition.

More... »

WuXi Reports 36% Revenue Growth, Prepares for Sale to Charles River

Wednesday, May 12, 2010 07:07 AM

Chinese contract research organization WuXi Pharmatech reported 36% revenue growth in what may be one of the company’s last quarterly earnings statements if an acquisition by Charles River Laboratories goes through.

More... »

Charles River Labs to Acquire WuXi PharmaTech for $1.6B

Monday, April 26, 2010 08:32 AM

Preclinical contract research organization (CRO) Charles River Laboratories announced this morning plans to acquire Chinese CRO Wuxi PharmaTech in a deal valued at $1.6 billion.

More... »

Chiltern Buys Stake in IRT Company

Wednesday, April 14, 2010 07:00 AM

UK-based contract research organization (CRO) Chiltern International is now a minority shareholder in San Francisco technology company endpoint Clinical, a company that provides integrated response technology (IRT) for clinical trials.

More... »